FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2259886495> ?p ?o ?g. }

• W2259886495 endingPage "254" @default.
• W2259886495 startingPage "246" @default.
• W2259886495 abstract "PURPOSE To determine whether early intensification with 12 courses of intravenous methotrexate and intravenous mercaptopurine (IVMTX/IVMP) is superior to 12 courses of repetitive, low-dose oral MTX with I.V. MP (LDMTX/IVMP) for prevention of relapse in children with lower-risk B-lineage acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS Seven hundred nine patients were entered onto the study. Vincristine, prednisone, and asparaginase were used for remission induction. Patients were randomized to receive intensification with either IVMTX 1,000 mg/m2 plus IVMP 1,000 mg/m2 (regimen A) or LDMTX 30 mg/m2 every 6 hours for six doses with IVMP 1,000 mg/m2 (regimen B). Twelve courses were administered at 2-week intervals. Triple intrathecal therapy (TIT) was used for CNS prophylaxis. Continuation therapy included standard oral MP, weekly MTX, and TIT every 12 weeks for 2 years. RESULTS Six hundred ninety-nine (99%) patients achieved remission. Three hundred forty-nine were assigned to regimen A and 350 to regimen B. The estimated 4-year continuous complete remission (CCR) rate for patients treated with regimen A is 80.3% (SE = 2.9%) and with regimen B is 75.9% (SE = 3.1%). By log-rank analysis, regimen A demonstrated superior CCR (P = .013). Transient neutropenia/thrombocytopenia, bacterial sepsis, neurotoxicity, stomatitis, and hospitalizations were more frequent among patients treated on regimen A. CONCLUSION Intensification with IVMTX/IVMP is more effective than LDMTX/IVMP for prevention of relapse in children with B-precursor ALL at lower risk for relapse." @default.
• W2259886495 created "2016-06-24" @default.
• W2259886495 creator A5000492905 @default.
• W2259886495 creator A5012609090 @default.
• W2259886495 creator A5031268622 @default.
• W2259886495 creator A5036295405 @default.
• W2259886495 creator A5056916024 @default.
• W2259886495 creator A5062115856 @default.
• W2259886495 creator A5074466450 @default.
• W2259886495 date "1998-01-01" @default.
• W2259886495 modified "2023-10-18" @default.
• W2259886495 title "Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial." @default.
• W2259886495 cites W120469029 @default.
• W2259886495 cites W1267962195 @default.
• W2259886495 cites W1487408013 @default.
• W2259886495 cites W1507403192 @default.
• W2259886495 cites W1527938262 @default.
• W2259886495 cites W1539446303 @default.
• W2259886495 cites W1544856870 @default.
• W2259886495 cites W1556688334 @default.
• W2259886495 cites W1587946844 @default.
• W2259886495 cites W1589458972 @default.
• W2259886495 cites W1846828978 @default.
• W2259886495 cites W1908994222 @default.
• W2259886495 cites W1909111805 @default.
• W2259886495 cites W1921877523 @default.
• W2259886495 cites W1925805959 @default.
• W2259886495 cites W1939497674 @default.
• W2259886495 cites W195883502 @default.
• W2259886495 cites W1979300931 @default.
• W2259886495 cites W1986666475 @default.
• W2259886495 cites W1988055549 @default.
• W2259886495 cites W2038252730 @default.
• W2259886495 cites W2043394791 @default.
• W2259886495 cites W2050615063 @default.
• W2259886495 cites W2081189233 @default.
• W2259886495 cites W2085642107 @default.
• W2259886495 cites W2090134648 @default.
• W2259886495 cites W2096966147 @default.
• W2259886495 cites W2119685895 @default.
• W2259886495 cites W2129762592 @default.
• W2259886495 cites W2134190122 @default.
• W2259886495 cites W2138205116 @default.
• W2259886495 cites W2147996630 @default.
• W2259886495 cites W2152829853 @default.
• W2259886495 cites W2163210431 @default.
• W2259886495 cites W2170012309 @default.
• W2259886495 cites W2175335327 @default.
• W2259886495 cites W2252501309 @default.
• W2259886495 cites W2264626034 @default.
• W2259886495 cites W2268597539 @default.
• W2259886495 cites W2278728288 @default.
• W2259886495 cites W2324850315 @default.
• W2259886495 cites W2343323057 @default.
• W2259886495 cites W2418545696 @default.
• W2259886495 cites W2418597353 @default.
• W2259886495 cites W307794556 @default.
• W2259886495 cites W3146256575 @default.
• W2259886495 cites W69686021 @default.
• W2259886495 cites W2995133996 @default.
• W2259886495 doi "https://doi.org/10.1200/jco.1998.16.1.246" @default.
• W2259886495 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9440749" @default.
• W2259886495 hasPublicationYear "1998" @default.
• W2259886495 type Work @default.
• W2259886495 sameAs 2259886495 @default.
• W2259886495 citedByCount "86" @default.
• W2259886495 countsByYear W22598864952012 @default.
• W2259886495 countsByYear W22598864952013 @default.
• W2259886495 countsByYear W22598864952014 @default.
• W2259886495 countsByYear W22598864952017 @default.
• W2259886495 countsByYear W22598864952020 @default.
• W2259886495 countsByYear W22598864952022 @default.
• W2259886495 crossrefType "journal-article" @default.
• W2259886495 hasAuthorship W2259886495A5000492905 @default.
• W2259886495 hasAuthorship W2259886495A5012609090 @default.
• W2259886495 hasAuthorship W2259886495A5031268622 @default.
• W2259886495 hasAuthorship W2259886495A5036295405 @default.
• W2259886495 hasAuthorship W2259886495A5056916024 @default.
• W2259886495 hasAuthorship W2259886495A5062115856 @default.
• W2259886495 hasAuthorship W2259886495A5074466450 @default.
• W2259886495 hasConcept C126322002 @default.
• W2259886495 hasConcept C141071460 @default.
• W2259886495 hasConcept C2776694085 @default.
• W2259886495 hasConcept C2776755627 @default.
• W2259886495 hasConcept C2777063308 @default.
• W2259886495 hasConcept C2777173762 @default.
• W2259886495 hasConcept C2778461978 @default.
• W2259886495 hasConcept C2778720950 @default.
• W2259886495 hasConcept C2778850193 @default.
• W2259886495 hasConcept C2779429289 @default.
• W2259886495 hasConcept C2781059491 @default.
• W2259886495 hasConcept C2781107101 @default.
• W2259886495 hasConcept C2781413609 @default.
• W2259886495 hasConcept C2909962599 @default.
• W2259886495 hasConcept C42219234 @default.
• W2259886495 hasConcept C71924100 @default.
• W2259886495 hasConcept C90924648 @default.
• W2259886495 hasConceptScore W2259886495C126322002 @default.

• next